Inflammopharmacology最新文献_第6页

Uncovering the intricacies of IGF-1 in Alzheimer's disease: new insights from regulation to therapeutic targeting.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-01-30 DOI: 10.1007/s10787-025-01641-0

Navpreet Kaur, Khadga Raj Aran

{"title":"Uncovering the intricacies of IGF-1 in Alzheimer's disease: new insights from regulation to therapeutic targeting.","authors":"Navpreet Kaur, Khadga Raj Aran","doi":"10.1007/s10787-025-01641-0","DOIUrl":"10.1007/s10787-025-01641-0","url":null,"abstract":"Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-β plaques and tau tangles, leading to cognitive decline and dementia. Insulin-like Growth Factor-1 (IGF-1) is similar in structure to insulin and is crucial for cell growth, differentiation, and regulating oxidative stress, synaptic plasticity, and mitochondrial function. IGF-1 exerts its physiological effects by binding to the IGF-1 receptor (IGF-1R) and activating PI3K/Akt pathway. In addition to the physiological activities in the brain, numerous studies point to a potential protective role of the IGF-1 pathway in the pathogenesis of neurodegenerative diseases, such as AD. Interestingly, patients with AD often exhibit altered insulin and IGF-1 levels, along with an inadequate insulin response. Dysregulation of IGF-1 signaling contributes to hyperphosphorylation of tau, NFT accumulation, increased β- and γ-secretase activity, elevated Aβ production, and impaired Aβ clearance, highlighting the need to explore the role of this signaling for potential therapeutic targets of AD. This review explores the role of IGF signaling in AD pathology, highlighting IGF-1 as a promising therapeutic target due to its significant involvement in disease mechanisms. Modulating IGF-1 activity could help mitigate neurodegeneration and preserve cognitive function in AD. A comprehensive understanding of the mechanisms underlying IGF-1 dysregulation is crucial for developing targeted therapeutic strategies to address the complex and multifaceted nature of AD.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1311-1330"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ferroptosis role in complexity of cell death: unrevealing mechanisms in Parkinson's disease and therapeutic approaches.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-25 DOI: 10.1007/s10787-025-01672-7

Anupam Awasthi, Kousik Maparu, Shamsher Singh

{"title":"Ferroptosis role in complexity of cell death: unrevealing mechanisms in Parkinson's disease and therapeutic approaches.","authors":"Anupam Awasthi, Kousik Maparu, Shamsher Singh","doi":"10.1007/s10787-025-01672-7","DOIUrl":"10.1007/s10787-025-01672-7","url":null,"abstract":"Parkinson's disease (PD), a common neurodegenerative disorder, is characterized by progressive loss of dopaminergic neurons, and accumulation of α-synuclein in the substantial nigra. Emerging evidence identifies ferroptosis as a regulated iron-dependent cell death mechanism marked by excessive lipid peroxidation (LPO) as a key contributor to PD pathogenesis. Ferroptosis is intertwined with critical disease processes such as aggregation of α-synuclein protein, oxidative stress generation, mitochondrial alteration, iron homeostasis dysregulation, and neuroinflammation. This mechanism disrupts cellular homeostasis by impairing iron metabolism and antioxidant pathways like the xc-/glutathione/GPX4 axis and the CoQ10 pathway. This review consolidates current advancements in understanding ferroptosis in these mechanisms, increasing interest in contribution to PD pathology. In addition, it explores the latest developments in ferroptosis-targeting pharmacological agents, including their application in the preclinical and clinical study, and highlights their potential to revolutionize PD management. Unraveling the interplay between ferroptosis and PD offers a transformative perspective, paving the way for innovative therapies to combat this debilitating disease condition.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1271-1287"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dissolving microneedle patch for transdermal delivery of perindopril erbumine.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-26 DOI: 10.1007/s10787-025-01696-z

Zunaira Altaf, Zulcaif Ahmad, Asif Mahmood, Saniia Shchinar, Riffat Latif

{"title":"Dissolving microneedle patch for transdermal delivery of perindopril erbumine.","authors":"Zunaira Altaf, Zulcaif Ahmad, Asif Mahmood, Saniia Shchinar, Riffat Latif","doi":"10.1007/s10787-025-01696-z","DOIUrl":"10.1007/s10787-025-01696-z","url":null,"abstract":"Perindopril Erbumine is a widely used angiotensin-converting enzyme (ACE) inhibitor for managing hypertension and cardiovascular diseases. Its dual action of lowering blood pressure and mitigating inflammation makes it a cornerstone treatment in these conditions. However, its oral administration often results in suboptimal bioavailability and gastrointestinal side effects. This study aimed to develop and characterize a dissolving microneedle (dMN) patch for the transdermal delivery of Perindopril Erbumine to enhance therapeutic efficacy and patient compliance. A Perindopril Erbumine-loaded microneedle patch was fabricated using chitosan and polyvinyl alcohol (PVA) using the solvent casting method. The microneedle patch was evaluated for physical properties, mechanical strength, drug loading, and moisture content. Ex-vivo permeation through rat skin and in-vivo pharmacokinetic studies in rabbits was conducted to compare its performance with a marketed oral Perindopril Erbumine formulation. The developed patch demonstrated effective skin penetration, controlled drug release, and a six-fold enhancement in cumulative drug permeation (82.45% ± 1.54) compared to the oral solution (14.32% ± 1.60). The pharmacokinetic study revealed prolonged drug release, with a 7.9-fold increase in half-life (7.739 ± 0.243 h vs. 0.986 ± 0.93 h) and a significantly higher area under the curve (AUC) for the microneedle patch. Skin irritation studies confirmed the biocompatibility of the formulation, with no significant adverse effects observed. These findings highlight the potential of Perindopril Erbumine-loaded dissolving microneedles as a promising transdermal delivery system for improved therapeutic outcomes in managing hypertension and inflammation-related vascular conditions, potentially reducing inflammation through enhanced and targeted drug delivery.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1381-1391"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143500832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nano-interventions for dengue: a comprehensive review of control, detection and treatment strategies.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-20 DOI: 10.1007/s10787-025-01655-8

Samia Shaikh, Padakanti Sandeep Chary, Neelesh Kumar Mehra

{"title":"Nano-interventions for dengue: a comprehensive review of control, detection and treatment strategies.","authors":"Samia Shaikh, Padakanti Sandeep Chary, Neelesh Kumar Mehra","doi":"10.1007/s10787-025-01655-8","DOIUrl":"10.1007/s10787-025-01655-8","url":null,"abstract":"Dengue, a formidable life-threatening malady, currently exerts a profound impact upon the Western Pacific and Southeast-Asian developing and underdeveloped nations. The intricacies inherent in addressing dengue are manifold, requiring a concerted effort not only towards vector control but also the implementation of efficacious host treatments to forestall the progression of the disease into severe manifestations, such as hemorrhage and shock. The only vaccine available for dengue in the market is DENGVAXIA, with several other vaccine candidates which are currently in the clinical developmental stages. However, DENGVAXIA, owing to incidences of adverse events in among children, was withdrawn in Philippines. This warrants the development of new safer vaccine candidates. The existent control strategies, regrettably, demonstrate inadequacy in effectively mitigating the rampant dissemination of this ailment. Moreover, the diagnostic and therapeutic modalities exhibit potential for refinement, specifically through precision diagnostics and tailored therapeutic interventions, to enhance the precision and efficacy of dengue management. This comprehensive review endeavors to provide an in-depth elucidation of the utilization of nanotechnology-based approaches synergistically integrated with conventional methodologies in the overarching domains of dengue control, diagnosis, and treatment.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"979-1011"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of intramuscular vs intra-articular betamethasone injection on pain and inflammatory factors among patients with severe traumatic knee osteoarthritis. 肌内注射倍他米松与关节内注射倍他米松对严重外伤性膝骨关节炎患者疼痛及炎症因子的影响。

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-01-13 DOI: 10.1007/s10787-024-01637-2

Yongjun Liu, Hongwei Gao, Bin Du, Qianwen Huo

{"title":"Effect of intramuscular vs intra-articular betamethasone injection on pain and inflammatory factors among patients with severe traumatic knee osteoarthritis.","authors":"Yongjun Liu, Hongwei Gao, Bin Du, Qianwen Huo","doi":"10.1007/s10787-024-01637-2","DOIUrl":"10.1007/s10787-024-01637-2","url":null,"abstract":"Objective: The aim of this study was to comprehensively investigate the clinical efficacy of intraoperative local joint injection and intramuscular injection of betamethasone in patients with severe traumatic knee osteoarthritis (KOA).Methods: 80 patients with severe traumatic KOA undergoing total knee arthroplasty were retrospectively recruited and rolled into S1 group (intra-articular injection of ropivacaine + betamethasone and isotonic saline mixture at joint incision), S2 group (muscle local injection of betamethasone before incision closure, simultaneously intra-articular injection of ropivacaine + isotonic saline mixture at joint incision), and D group (intra-articular injection of ropivacaine + isotonic saline mixture at the joint incision). Visual analog scale (VAS) score, serum inflammatory factors (IFs), hospital for special surgery (HSS)score, Pittsburgh sleep quality index (PSQI), and adverse reaction events (AREs) were analyzed.Results: Pain scores of patients in all three groups decreased drastically over time on postoperative days (PDs) 1, 2, and 3, with the scores in S1 and S2 groups markedly inferior to D group (P < 0.05). HSS scores of patients in S1 and S2 groups at postoperative months 1, 3, and 6 were considerably superior to those in D group (P < 0.05). PSQI scores of patients in S1 and S2 groups at postoperative months 1, 3, and 6 were notably inferior to those in D group (P < 0.05).Conclusion: Both intraoperative local joint injection and muscle injection of betamethasone are effective in patients with severe traumatic KOA.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1349-1356"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Zataria multiflora supplementation on pro- or anti-inflammatory markers: a systematic review and meta-analysis of randomized placebo-controlled trials.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-24 DOI: 10.1007/s10787-025-01668-3

Alireza Moradi, Farzin Aslani, Mohammad Hossein Boskabady, Yasamin Pahlavan, Mohammad Reza Aslani

{"title":"Effect of Zataria multiflora supplementation on pro- or anti-inflammatory markers: a systematic review and meta-analysis of randomized placebo-controlled trials.","authors":"Alireza Moradi, Farzin Aslani, Mohammad Hossein Boskabady, Yasamin Pahlavan, Mohammad Reza Aslani","doi":"10.1007/s10787-025-01668-3","DOIUrl":"10.1007/s10787-025-01668-3","url":null,"abstract":"The aim of this study was to investigate the effectiveness of Zataria multiflora and carvacrol supplementation on inflammatory markers (IL-2, IL-4, IL-5, IL-6, TNF-α, IL-8, IL-10, interferon gamma (IFN-γ), C-reactive protein (CRP), monocyte chemotactic protein 1 (MCP-1), epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF)) by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs).The exploration of literature was conducted until August 2024 on databases like PubMed/Medline, Web of Science, Scopus, Cochrane CENTRAL, and Google Scholar. The current study incorporated trial studies examining how oral supplements of Zataria multiflora and carvacrol impact concentrations of inflammatory markers. By utilizing a random effects model, the mean differences (SMD) and 95% confidence intervals (CI) were pooled for analysis of the results. The Cochrane Q and I2 values were used to evaluate heterogeneity. The meta-analysis included ten cases, with 562 participants in the Zataria multiflora group and 700 in the control group. A significant decrease in the levels of various cytokines including IL-2, IL-4, IL-5, IL-6, IL-8, CRP, EGF, VEGF, and MCP-1 was observed with the consumption of Zataria multiflora along with a noteworthy increase in both IFN-γ and IL-10. However, TNF-α levels remained unaffected by the intervention involving Zataria multiflora and carvacrol. It should be noted that limitations of this study include the fact that it draws from research in Iran, encompasses a range of different diseases, and overlooks potential confounders like smoking, physical activity, and diet. In summary, the results suggested that Zataria multiflora and carvacrol can be beneficial for reducing inflammation.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1255-1270"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effects of aqueous extract of Waltheria indica (Sterculiaceae) leafy stems on acetic acid-induced ulcerative colitis in rats.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-11 DOI: 10.1007/s10787-025-01651-y

Michel Archange Fokam Tagne, Paul Aimé Noubissi, Angèle Foyet Fondjo, Laurelle Nono Njomguep, Joseph Ngakou Mukam, Sélestin Sokeng Dongmo, René Kamgang

{"title":"Effects of aqueous extract of Waltheria indica (Sterculiaceae) leafy stems on acetic acid-induced ulcerative colitis in rats.","authors":"Michel Archange Fokam Tagne, Paul Aimé Noubissi, Angèle Foyet Fondjo, Laurelle Nono Njomguep, Joseph Ngakou Mukam, Sélestin Sokeng Dongmo, René Kamgang","doi":"10.1007/s10787-025-01651-y","DOIUrl":"10.1007/s10787-025-01651-y","url":null,"abstract":"Ulcerative colitis is one of the inflammatory bowel diseases that manifest itself by uncontrolled inflammation of colon. The objective of this work was to evaluate the effects of aqueous extract of Waltheria indica on acetic acid-induced ulcerative colitis in rats. Six (6) groups of five (5) rats each, were anesthetized with a ketamine (50 mg/kg)/valium (10 mg/kg) mixture after eighteen (18) fasting hours. Colitis was induced by intrarectal administration of 1 mL of acetic acid (5%) in animals. Five (5) hours later, the normal control (NC) and the colitis control (CC) received distilled water (10 mL/kg bw), the positive control (Pre5) received prednisolone (5 mg/kg) and the other three test groups received the W. indica extract at 50 (Wi50), 100 (Wi100) and 200 (Wi200) mg/kg bw, orally for 7 days. At the end of the treatment, the animals were sacrificed and the blood was collected from the carotid artery, part in the ethylenediaminetetraacetate (EDTA) tube for hematological analyzes and part in dry tubes for biochemical assays. The abdomen was then opened, the colon, liver, spleen, lungs and heart were removed, drained, weighed and the indexes of each organ were determined. The extract at 200 mg/kg reduced myeloperoxidase (MPO) and inhibited the production of interleukin-1 beta (IL-1β) and interleukin-6(IL-6) in the colon and serum. The extract significantly increased the blood platelet level of the colitis rats. Thus, these results suggest that Walthera indica extract may have therapeutic potential for the treatment of inflammatory bowel diseases.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1505-1516"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long COVID has variable incidence and clinical presentations: our 6-country collaborative study.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-02-21 DOI: 10.1007/s10787-025-01640-1

Sandor Szabo, Iryna Muzyka, Veronika Muller, Attila J Szabo, Attila Szijártó, Klara Gyires, Tamas Doczi, Jozsef Janszky, Andreas Stengel, Siri Göpel, Antonia Trichopoulou, Rafael Diaz, Nicte Camacho, George Malatinszky, Nils Lambrecht, Oksana Zayachkivska

{"title":"Long COVID has variable incidence and clinical presentations: our 6-country collaborative study.","authors":"Sandor Szabo, Iryna Muzyka, Veronika Muller, Attila J Szabo, Attila Szijártó, Klara Gyires, Tamas Doczi, Jozsef Janszky, Andreas Stengel, Siri Göpel, Antonia Trichopoulou, Rafael Diaz, Nicte Camacho, George Malatinszky, Nils Lambrecht, Oksana Zayachkivska","doi":"10.1007/s10787-025-01640-1","DOIUrl":"10.1007/s10787-025-01640-1","url":null,"abstract":"Following the acute COVID-19 disease, many countries see long-time sequences of this infectious disease, commonly known as Long COVID. This seems to be a multi-organ inflammatory chronic condition of variable intensity and incidence, partly due to the retention of the virus or viral particles in several organs. Based on our 6-country (4 in Europe, 2 from North America) collaborative investigations, we found that the incidence of Long COVID varied from 46 (Mexico) to 17% (Ukraine), the average being 25%. In a summary evaluation of all 6 countries, we characterized as \"general\" the most frequent presenting signs and symptoms: fatigue (47%), hair loss (39.2%), and myalgia (35%), but no two countries demonstrated the same top 3 clinical signs/symptoms. Hence, we promote the following 3 key points: 1. to expand international collaborations to better understand not only the prevalence and incidence of Long COVID but also to gain insights into the pathogenesis, and identify predisposing factors and diagnostic biomarkers of Long COVID; 2. find or develop new drugs for the treatments of Long COVID and identify appropriate rehabilitation, potentially organ-specific strategies; 3. most importantly, to start long-term observational studies (e.g., for 5-10-15 years) to identify potential increased cancer incidence in any organ, especially, since we know that certain viruses are carcinogens.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"1531-1535"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanostructured lipid carriers in Rheumatoid Arthritis: treatment, advancements and applications.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 Epub Date: 2025-03-02 DOI: 10.1007/s10787-025-01669-2

Swarnika Sharma, Rashmi Ghosh, Arockia Babu Marianesan, Sumaya Hussain, Jai Deo Pandey, Manish Kumar

{"title":"Nanostructured lipid carriers in Rheumatoid Arthritis: treatment, advancements and applications.","authors":"Swarnika Sharma, Rashmi Ghosh, Arockia Babu Marianesan, Sumaya Hussain, Jai Deo Pandey, Manish Kumar","doi":"10.1007/s10787-025-01669-2","DOIUrl":"10.1007/s10787-025-01669-2","url":null,"abstract":"Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and causes pain, swelling, and deformity. Current treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs, often have limited efficacy and adverse side effects. Nanostructured lipid carriers (NLCs) are promising drug delivery agents for treating RA. NLCs are comprised of solid and liquid lipids, forming a nanostructured matrix that enhances drug solubility, stability, and controlled release. They offer advantages over traditional carriers such as improved skin penetration, increased bioavailability, and reduced systemic side effects. Topical NLC formulations show improved stability and skin absorption, targeting drugs specifically to the affected joints, thus reducing the required dose and systemic exposure. Studies on NLCs for delivering anti-inflammatory and antirheumatic drugs, such as methotrexate, indomethacin, and curcumin, in RA animal models indicate the potential for improved therapeutic efficacy and safety. NLCs represent a promising approach for targeted RA drug delivery, offering better efficacy, fewer side effects, and higher patient compliance. However, further research is needed to optimize NLC formulations and evaluate their clinical efficacy and safety in RA patients. The development of NLC-based drug delivery systems for RA treatment may lead to more effective and well-tolerated therapies, thereby improving the quality of life of patients with this debilitating disease.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"941-958"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Extracellular vesicles as therapeutic agents in rheumatoid arthritis: a systematic review of current evidence.

IF 4.6 2区医学

Inflammopharmacology Pub Date : 2025-03-01 DOI: 10.1007/s10787-025-01670-9

Xiaolei Miao, Amirreza Ghafourian, Mahdi Karimi Khaneghah, Seyed Mohammad Ayyoubzadeh, Reza Afrisham, Mahnaz Ahmadi

{"title":"Extracellular vesicles as therapeutic agents in rheumatoid arthritis: a systematic review of current evidence.","authors":"Xiaolei Miao, Amirreza Ghafourian, Mahdi Karimi Khaneghah, Seyed Mohammad Ayyoubzadeh, Reza Afrisham, Mahnaz Ahmadi","doi":"10.1007/s10787-025-01670-9","DOIUrl":"10.1007/s10787-025-01670-9","url":null,"abstract":"Rheumatoid arthritis (RA) is defined as a chronic autoimmune disease that severely influences a patient's quality of life. Extracellular vesicles (EVs) have gained much attention in recent years as one of the most potent therapeutic agents for the treatment of RA. A systematic review was performed with the purpose of assessing the current evidence relating to the therapeutic applications of EVs in RA. The systematic search was performed in the databases of PubMed, Scopus, and Web of Science, from inception times to September 2024. All studies investigating the use of EVs for the treatment of RA were included. The quality appraisal of selected articles and data extraction regarding EV characteristics, therapeutic applications, and associated outcomes were performed. Of the 1418 initially identified articles, 59 studies met inclusion criteria. Regarding their cellular origins, most EVs were derived from mesenchymal stem cells, followed by immune cells. The main therapeutic mechanisms included modulation of the immune response, reduction of inflammation, and repair of tissues. Recent trends are toward increasing interest in engineered EVs and combination therapies. Indeed, most studies reported positive outcomes with regard to lowered inflammation and improved joint function. On the other hand, standardization of the metrics of evaluation considerably varied between different studies. EVs are promising therapeutic agents in the treatment of RA by modulating immune responses. Standardization, delivery systems, and clinical translation are challenges yet to be overcome. Future studies will be directed to optimize EV engineering, targeted delivery systems, and large-scale clinical trials.","PeriodicalId":13551,"journal":{"name":"Inflammopharmacology","volume":" ","pages":"889-915"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0